@karaldavis.bsky.social
What underlies antigen loss after CD19 or CD22 targeted CAR-T? Pablo Domizi and team masterfully demonstrate the important role of IKAROS in antigen loss resistance in our new paper out in @natcomms.nature.com rdcu.be/eiViL
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies
Nature Communications - Antigen escape relapse remains a major obstacle when treating B-cell malignancies with immunotherapies. Here, the authors show that IKAROS regulates the surface expression...
rdcu.be
April 24, 2025 at 2:58 PM
What underlies antigen loss after CD19 or CD22 targeted CAR-T? Pablo Domizi and team masterfully demonstrate the important role of IKAROS in antigen loss resistance in our new paper out in @natcomms.nature.com rdcu.be/eiViL